Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VIVO Cannabis Inc. V.PDA


Primary Symbol: VVCIF

VIVO Cannabis Inc is a Canada-based company. It is involved in the production and sale of medical and recreational cannabis and the provision of cannabis-related medical information and services in Canada. The company's operating segment includes Cannabis, Patient Clinics, and Corporate. It generates maximum revenue from the Cannabis segment. The company has a presence across three geographical locations - Canada, Germany, and Australia.


OTCQB:VVCIF - Post by User

Comment by Schaffhausenon Dec 05, 2020 7:58am
369 Views
Post# 32043457

RE:RE:RE:VIVO is an Instantly Accretive Takeover Target

RE:RE:RE:VIVO is an Instantly Accretive Takeover Target
A simple theory would be based on equivalent Market Cap/Revenue of the buying company. That is to say that since VIVO would be generally outperforming the potential buying LP cohort (considering VIVO turns profit in 2021, ahead of the potential buying company). The price of VIVO in a buyout would be justifiable at an earnings multiple at or slightly above that of the buying company. Say VIVO 2021 net revenue is estimated at 60M then, with a current market cap of $55M, VIVO would have a MC/revenue ratio of 0.92. Other LPS have varying ratios, MUCH HIGHER THAN VIVO, and for the large LPS, that ratio is as high as 27 for Canopy Growth! Now, having said that, Canopy is on the far end of the spectrum and its shares are grossly overvalued. In line with other mid-cap LPS I think a ratio of 3 is a steal of VIVO, putting the price at 0.55. Once VIVO profitability is reached I think that the ratio could be closer to 6, putting SP above 1.00 again and well away from the current opportunistic buyout status. Cheers, Schaff
<< Previous
Bullboard Posts
Next >>